HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls

H Zhang, BS Finkelman, MG Ettel, MJ Velez… - …, 2024 - Wiley Online Library
The significant clinical benefits of human epidermal growth factor receptor 2 (HER2)‐
targeted therapeutic agents have revolutionized the clinical treatment landscape in a variety …

[HTML][HTML] Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with …

V Angerilli, F Ghelardi, F Nappo, F Grillo… - … -Research and Practice, 2024 - Elsevier
Abstract Claudin-18.2 (CLDN18. 2) is a member of the tight junction protein family and is a
highly selective biomarker with often abnormal expression during the occurrence and …

Gastric Carcinoma in Autoimmune Gastritis: A Histopathologic and Molecular Study

V Angerilli, A Vanoli, G Celin, C Ceccon, J Gasparello… - Modern Pathology, 2024 - Elsevier
Patients with autoimmune gastritis (AIG) have a 13-fold risk of developing type-1
neuroendocrine tumors, whereas the risk for gastric adenocarcinoma is still uncertain. Here …

Prognostic and predictive role of YKL-40 in anal squamous cell carcinoma: a serological and tissue-based analysis in a multicentric cohort

A Gambella, R Senetta, EC Falco, AA Ricci… - Frontiers in …, 2024 - frontiersin.org
Introduction Anal squamous cell carcinoma (ASC) is a rare gastrointestinal malignancy
showing an increased incidence over the past decades. YKL-40 is an immune modulator …

Her2 low (but not negative): the newest biomarker on the block for gastro-oesophageal adenocarcinoma

JF Hechtman - Journal of Clinical Pathology, 2023 - jcp.bmj.com
In this issue of Journal of Clinical Pathology, Angerilli et al provide a detailed survey of the
prevalence and characteristics of HER2 expression by immunohistochemistry (IHC) in …